vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $151.1M, roughly 1.9× STURM RUGER & CO INC). On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 3.6%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 5.1%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
ACAD vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $151.1M |
| Net Profit | $273.6M | — |
| Gross Margin | 90.8% | 17.8% |
| Operating Margin | 6.1% | 2.3% |
| Net Margin | 96.3% | — |
| Revenue YoY | 9.4% | 3.6% |
| Net Profit YoY | 90.3% | — |
| EPS (diluted) | $1.61 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $151.1M | ||
| Q3 25 | $278.6M | $126.8M | ||
| Q2 25 | $264.6M | $132.5M | ||
| Q1 25 | $244.3M | $135.7M | ||
| Q4 24 | $259.6M | $145.8M | ||
| Q3 24 | $250.4M | $122.3M | ||
| Q2 24 | $242.0M | $130.8M | ||
| Q1 24 | $205.8M | $136.8M |
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | $1.6M | ||
| Q2 25 | $26.7M | $-17.2M | ||
| Q1 25 | $19.0M | $7.8M | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | $4.7M | ||
| Q2 24 | $33.4M | $8.3M | ||
| Q1 24 | $16.6M | $7.1M |
| Q4 25 | 90.8% | 17.8% | ||
| Q3 25 | 92.2% | 15.1% | ||
| Q2 25 | 92.2% | 3.9% | ||
| Q1 25 | 91.7% | 22.0% | ||
| Q4 24 | 91.6% | 22.8% | ||
| Q3 24 | 92.5% | 18.5% | ||
| Q2 24 | 92.5% | 22.3% | ||
| Q1 24 | 88.8% | 21.5% |
| Q4 25 | 6.1% | 2.3% | ||
| Q3 25 | 12.8% | -2.7% | ||
| Q2 25 | 12.2% | -15.6% | ||
| Q1 25 | 7.9% | 6.2% | ||
| Q4 24 | 59.1% | 7.8% | ||
| Q3 24 | 12.6% | 3.1% | ||
| Q2 24 | 12.6% | 6.9% | ||
| Q1 24 | 7.4% | 5.5% |
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | 1.2% | ||
| Q2 25 | 10.1% | -13.0% | ||
| Q1 25 | 7.8% | 5.7% | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | 3.9% | ||
| Q2 24 | 13.8% | 6.3% | ||
| Q1 24 | 8.0% | 5.2% |
| Q4 25 | $1.61 | $0.22 | ||
| Q3 25 | $0.42 | $0.10 | ||
| Q2 25 | $0.16 | $-1.05 | ||
| Q1 25 | $0.11 | $0.46 | ||
| Q4 24 | $0.86 | $0.62 | ||
| Q3 24 | $0.20 | $0.28 | ||
| Q2 24 | $0.20 | $0.47 | ||
| Q1 24 | $0.10 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $92.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $283.8M |
| Total Assets | $1.6B | $342.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $92.5M | ||
| Q3 25 | $258.0M | $80.8M | ||
| Q2 25 | $253.6M | $101.4M | ||
| Q1 25 | $217.7M | $108.3M | ||
| Q4 24 | $319.6M | $105.5M | ||
| Q3 24 | $155.1M | $96.0M | ||
| Q2 24 | $177.1M | $105.6M | ||
| Q1 24 | $204.7M | $115.3M |
| Q4 25 | $1.2B | $283.8M | ||
| Q3 25 | $917.3M | $279.6M | ||
| Q2 25 | $822.4M | $289.3M | ||
| Q1 25 | $765.2M | $321.5M | ||
| Q4 24 | $732.8M | $319.6M | ||
| Q3 24 | $577.2M | $314.9M | ||
| Q2 24 | $516.7M | $321.5M | ||
| Q1 24 | $464.0M | $332.0M |
| Q4 25 | $1.6B | $342.0M | ||
| Q3 25 | $1.3B | $342.3M | ||
| Q2 25 | $1.2B | $349.5M | ||
| Q1 25 | $1.1B | $379.0M | ||
| Q4 24 | $1.2B | $384.0M | ||
| Q3 24 | $976.9M | $373.5M | ||
| Q2 24 | $914.1M | $376.7M | ||
| Q1 24 | $855.1M | $385.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $15.5M |
| Free Cash FlowOCF − Capex | — | $12.3M |
| FCF MarginFCF / Revenue | — | 8.2% |
| Capex IntensityCapex / Revenue | — | 2.1% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $15.5M | ||
| Q3 25 | $74.3M | $12.9M | ||
| Q2 25 | $64.0M | $14.7M | ||
| Q1 25 | $20.3M | $11.1M | ||
| Q4 24 | $40.4M | $20.0M | ||
| Q3 24 | $63.2M | $9.4M | ||
| Q2 24 | $25.0M | $18.7M | ||
| Q1 24 | $29.1M | $7.3M |
| Q4 25 | — | $12.3M | ||
| Q3 25 | $73.9M | $7.0M | ||
| Q2 25 | — | $9.1M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | — | $16.4M | ||
| Q3 24 | $63.2M | $2.6M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | — | $5.6M |
| Q4 25 | — | 8.2% | ||
| Q3 25 | 26.5% | 5.5% | ||
| Q2 25 | — | 6.9% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | 25.2% | 2.1% | ||
| Q2 24 | — | 7.7% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | — | 2.1% | ||
| Q3 25 | 0.1% | 4.6% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | 0.0% | 5.5% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 8.15× | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | 1.43× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 1.98× | ||
| Q2 24 | 0.75× | 2.27× | ||
| Q1 24 | 1.76× | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
